HOME >> BIOLOGY >> NEWS
Different microarray systems more alike than previously thought

A multicenter comparison of equipment that can analyze the expression of thousands of genes at once to create a genetic "fingerprint," suggests these different microarray technologies are more alike than once thought.

Published in the May 2005 issue of Nature Methods, the study provides new hope that the mounds of information generated by these systems might actually be comparable, even though many different systems are used by many different laboratories.

"Biologists occasionally ask me what is the best platform on which to run microarray experiments, but there hasn't been a good answer to that question," said Rafael Irizarry, Ph.D., associate professor of biostatistics at the Johns Hopkins Bloomberg School of Public Health. "Now we see the possibility that it may not make much difference as long as the systems are used properly and the results reported properly."

The impact of such a finding is not insignificant, experts say, because these systems may ultimately allow scientists to uncover critical differences between, say, healthy and cancerous tissue. Unless laboratories can rely on each others' results, such findings would not have much value.

For the study, 10 laboratories in the Washington, D.C./Baltimore area were given identical samples of RNA -- DNA's cousin -- to analyze using a microarray platform of their choice. Five laboratories used commercially available Affymetrix microarrays, and five labs used either of two more flexible systems.

The Hopkins researchers noted that in the scientific literature some comparisons of different microarray systems found compatibility and some did not, and no study explored the possibility that a laboratory's methods of using a particular system affected the results.

"Given the amount of tinkering that occurs in some labs, my intuition was that different labs might obtain very different answers even when using the same platform," said Irizarry. "But we show that platfo
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
23-May-2005


Page: 1 2 3

Related biology news :

1. Different approach needed to protect brains of premature infants
2. All itches not created equal -- Different parts of brain activated depending on cause
3. Different coat color may not mean different species for lemurs
4. Different strategies underlie the ecology of microbial invasions
5. Different genes may cause autism in boys and girls
6. Different but equal: Settling the dosage compensation debate
7. NIH neuroscience microarray consortium launches high-throughput genotyping services
8. Chromosomal microarray analysis proves accurate
9. Study identifies common flaws in oncology microarray studies
10. Bayer HealthCare licenses Genomatix for microarray analysis
11. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool

Post Your Comments:
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
(Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
(Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
(Date:3/25/2015)... CA (PRWEB) March 25, 2015 ... for Novel Mechanism of Action in Neuromuscular Diseases ... 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the ... skeletal muscle troponin activator tirasemtiv in the journal ... Phase IIa “Evidence of Effect” or hypothesis-generating clinical ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: